Annual report pursuant to Section 13 and 15(d)

Note 4 - Acquisitions (Details Textual)

v3.21.2
Note 4 - Acquisitions (Details Textual) - USD ($)
$ in Thousands
8 Months Ended 12 Months Ended
Apr. 06, 2021
Apr. 02, 2021
Oct. 20, 2020
Jun. 04, 2019
Aug. 01, 2018
Jul. 02, 2018
Jun. 30, 2021
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2019
Payments to Acquire Businesses, Net of Cash Acquired, Total               $ 225,352 $ (0) $ 289,492
Gain (Loss) on Escrow Settlement               (0) 7,170 $ (0)
Changzhou Eminence Biotechnology [Member]                    
Business Acquisition, Percentage of Voting Interests Acquired     47.60%              
Business Combination, Consideration Transferred, Total     $ 9,800              
Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value     8,985       $ 8,985 8,985    
Payments to Acquire Businesses, Gross   $ 6,000                
Business Combination, Step Acquisition, Equity Interest in Acquiree, including Subsequent Acquisition, Percentage, Total   57.40%                
Variable Interest Entity, Primary Beneficiary, Maximum Loss Exposure, Portion Stemming from Initial Investment             15,800 15,800    
Goodwill, Purchase Accounting Adjustments             (963)      
Payments to Acquire Businesses, Net of Cash Acquired, Total     $ 9,765       9,765      
Changzhou Eminence Biotechnology [Member] | Developed Technology Rights [Member]                    
Finite-Lived Intangible Asset, Useful Life (Year)     13 years              
Changzhou Eminence Biotechnology [Member] | Customer Relationships [Member]                    
Finite-Lived Intangible Asset, Useful Life (Year)     10 years              
Acquisition of Asuragen, Inc. [Member]                    
Business Combination, Consideration Transferred, Total $ 233,887                  
Payments to Acquire Businesses, Net of Cash Acquired, Total 215,587                  
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High 105,000           105,000 105,000    
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual 7,100                  
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual $ (3,400)                  
Acquisition of Asuragen, Inc. [Member] | Developed Technology Rights [Member]                    
Finite-Lived Intangible Asset, Useful Life (Year) 14 years                  
Acquisition of Asuragen, Inc. [Member] | Customer Relationships [Member]                    
Finite-Lived Intangible Asset, Useful Life (Year) 16 years                  
Acquisition of Asuragen, Inc. [Member] | Trade Names [Member]                    
Finite-Lived Intangible Asset, Useful Life (Year) 5 years                  
Acquisition of Asuragen, Inc. [Member] | Noncompete Agreements [Member]                    
Finite-Lived Intangible Asset, Useful Life (Year) 3 years                  
QT Holdings Corporation [Member]                    
Payments to Acquire Businesses, Net of Cash Acquired, Total           $ 20,500     20,462  
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High           $ 51,000 51,000 51,000    
QT Holdings Corporation [Member] | Developed Technology Rights [Member]                    
Finite-Lived Intangible Asset, Useful Life (Year)           14 years        
Exosome Diagnostics, Inc [Member]                    
Payments to Acquire Businesses, Net of Cash Acquired, Total         $ 251,600       251,623  
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High         325,000          
Gain (Loss) on Escrow Settlement         $ 7,200          
Exosome Diagnostics, Inc [Member] | Developed Technology Rights [Member]                    
Finite-Lived Intangible Asset, Useful Life (Year)         15 years          
Exosome Diagnostics, Inc [Member] | Trade Names [Member]                    
Finite-Lived Intangible Asset, Useful Life (Year)         15 years          
B-MoGen [Member]                    
Goodwill, Purchase Accounting Adjustments                 300  
Finite-Lived Intangible Asset, Useful Life (Year)         14 years          
Payments to Acquire Businesses, Net of Cash Acquired, Total       $ 17,500         $ 17,448  
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High       38,000     $ 38,000 $ 38,000    
Business Combination, Step Acquisition, Equity Interest in Acquiree, Before Remeasurement to Fair Value       1,400            
Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain       $ 3,700            
B-MoGen [Member] | Developed Technology Rights [Member]                    
Finite-Lived Intangible Asset, Useful Life (Year)       14 years